Differential Responses to Immune Checkpoint Inhibitors are Governed by Diverse Mismatch Repair Gene Alterations.

Moh'd M Khushman Michael D Toboni Joanne Xiu Upender Manne Alex P Farrell Emil Lou Anthony Frank Shields Philip A Philip Mohamed E Salem Jim Abraham David B Spetzler John L Marshall Priya Jayachandran Michael J Hall Heinz-Josef Lenz Ibrahim Halil Sahin Andreas Seeber Matthew A Powell

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)

Patients with mutS co-loss experienced longer mOS in colorectal cancer and endometrial cancer and better response to ICIs in colorectal cancer. Among all explored biomarkers, NAL was higher in mutS co-loss and may be a potential driving factor for the observed better outcomes. TMB did not reliably predict NAL.

Keyphrases

insulin resistance
endometrial cancer
metabolic syndrome
quantum dots
copy number
genome wide
risk assessment
human health
dna methylation